The Utility of Prostate Health Index (PHI)
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses the utility of Prostate Health Index (PHI).
Clinical Pearls
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses the utility of Prostate Health Index (PHI).
- Since its introduction nearly twenty years ago, oncologists and researchers have been striving to improve PSA.
- Prostate Health Index (PHI) looks at pro-PSA and seems to adequately predict prostate cancer, as well as aggressiveness of disease and outcome.
- PHI score is typically used in men with high PSA.
Darolutamide Plus ADT Shows Promise in Treating Metastatic Prostate Cancer
July 17th 2024Findings from the phase 3 ARANOTE trial demonstrated an improvement in radiographic progression-free survival with darolutamide vs placebo plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
